ANG Lifesciences IPO Basis of Allotment

ANG LIFESCIENCES INDIA LIMITED
Corporate Identification Number: U24230PB2006PLC030341

Our Company was originally incorporated as 'ANG Lifesciences India Private Limited' on June 14, 2016 with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh as a private limited Company under the Companies Act, 1956. On conversion into public limited Company the name of our Company was changed to 'ANG Lifesciences India Limited' pursuant to Special resolution passed at the- Extra Ordinary General Meeting held on January 18, 2010 and a fresh Certificate of incorporation dated March 02, 2010 issued by thie Registrar of Companies. Punjab, Himachal Pradesh and Chandigarh. Our company was further converted into private limited Company and the name of our Company was changed to 'ANG Lifesciences India Private Limited' pursuant to special resolution passed at the Extra Ordinary General Meeting held on August 31, 2010 and a fresh certificate of incorporation was, issued by Registrar of Companies, Punjab. Himachal Pradesh and Chandigarh dated September 22, 2010 Subsequently, on conversion into public limited Company the name of our company again changed to 'ANG Lifesciences India Limited' pursuant to special resolution passed at the Extra Ordinary General Meeting held on May 04, 2016 and a fnesh certificate of incorporation dated May 18, 2016

Tel: +91 0183-5133455,5070118
Village Kishanpura, P.O. Manpura Baddi Nalagarh Road, Tehsil Nalagarh, Dist. Solan, Himachal Pradesh. - 173 205. | Tel: 92165 08075
Ms. Preeti Goel, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY: MR. RAJESH GUPTA AND MRS. SARUCHI GUPTA

BASIS OF ALLOTMENT

10.00 EACH OF ANG LIFESCIENCES INDIA LIMITED ('ANG' OR 'ALIL' OR 'THE COMPANY'
7000 PER EQUITY SHARE) ('ISSUE PRICE')
10 EACH AT A PRICE OF RS 80.00 PER EQUITY
61.44 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ('MARKET MAKER RESERVATION PORTION'). THE
10.00 EACH AT AN ISSUE PRICE OF
1139.20 LAKHS IS HEREINAFTER REFERRED TO AS THE 'NET ISSUE'. THE ISSUE AND THE NET ISSUE WILL
CONSTITUTE 28.95% AND 27.47%, RESPECTIVELY OFTHE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THIS ISSUE IS BEING MADE IN TERMS OF CHAPTER XB OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 (THE 'SEBI (ICDR) REGULATIONS'), AS AMENDED. THIS ISSUE IS A FIXED PRICE ISSUE AND ALLOCATION IN THE NET

The Equity Shares offered through the Prospectus are proposed to be listed on the SME Platform of BSE Limited. In terms of the Chapter XB of the SEBI (ICDR) Regulations 2009, as amended from time to time, our Company has received an approval letter dated May 02, 2017 from BSE Limiled ('BSE') for using its name in the Prospectus for listing of our shares on the SME Platform of BSE Limited. For The purpose of the Issue, the designated Stock Exchange will be the BSE The trading is proposed to be commenced on or about September 08, 2017, subject to receipt of listing and trading approvals from BSE Limited.

process by providing the details of the respective

SUBSCRIPTION DETAILS

The Issue has received 5165 applications for 1,15,66,400 Equity Shares (Before Technical Rejections but after invalid bids and bids not banked/blocked) (including Market Maker Application of 76,800 Equity Shares) resulting in 7.71 times subscription. After considering, a Technical Rejection case, the issue was subscribed 7.61 times (including the Market Maker Portion). The details of the applications received in the issue (before technical rejections) are as follows:

The Basis of Allotment was finalized In consultation with the Designated Stock Exchange - BSE Limited on September 05, 2017.

The Basis of Allotment to the Market Maker, at the Issue price of Rs 80 per Equity Share,
was finalised in consultation with BSE. The category was subscribed by 1 time. The total number of shares allotted in this category is 76800 Equity shares.
The Basis of Allotment to the Retail individual Investors, at the issue price of Rs 80 per Equity Share,
was finalized in consultation with BSE. The category was subscribed by 7.96 times. Total number of shares allotted in this category is 980800 Equity Shares

The Basis of Allotment to Other than Retail Individual Investors,
80 per Equity Share, was finalized in consultation with BSE. The category was subscribed by 7.99 times. Total number of shares allotted in

The Board of Directors of the Company at its meeting held on September 05, 2017 has taken on record the Basis of Allocation of Equity Shares approved by the Designated Stock Exchange viz. BSE and has authorized the corporate' action for allotment of shares in dematerialized form to various successful applicants. The CAN and allotment advice and/or rejection letters are being dispatched to the address of the Applicants as registered with the depositories / as filled in the application form on September 06, 2017. Further, the instructions to Self Certified Syndicate Banks being processed on September 06, 2017. In case the same is not received within prescribed time, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for

All capitalized terms used and not defined herein shall have Ihe respective meanings assigned to them in the Prospectus dated August 16,2017 ('Prospectus')

INVESTORS PLEASE NOTE

Big Share Services Private Limited at www.bigshareonline.com . All Future correspondence in this regard may kindly be addressed to the Registrar to the issue quoting full name of the First/ Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below: www.bigshareonline.com

The level of subscription should not be taken to be indicative of either the Market price of the Equity Shares on listing or the business prospects of ANG Lifesciences India Limited.